Greystone Associates Analysis Reveals Growing Interest and Development Activity
(Amherst, NH) – As the number of asthmatics, COPD, and allergy patients continues to grow, the upper respiratory treatment market is attracting a number of new companies – companies with some novel approaches to the problem of chronic airway inflammation. These companies are conducting ongoing research into the way asthma and COPD are diagnosed and measured, minimally invasive techniques to treat airway congestion, and technology improvements focused on systemic delivery of proteins and peptides as well as novel small molecule therapeutics.
New drug classes that focus on molecular targets are emerging as important tools for practitioners. Interest is growing among practitioners and their patients for treatments that are capable of delivering two drugs that can act in concert to mitigate the effects of airway inflammation better than a single drug. These combination products pair drugs with different indications to maximize patient relief
These findings are examined in a new and comprehensive survey written and researched by Greystone Associates. The report includes detailed analysis of new and development-stage treatment products and technologies and the emerging companies behind them.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
Comment and add to the story without registration, but keep the comments meaningful please. Links are not accepted.
